Advanced search
Publication Cover
Molecular and Cellular Biology Volume 24, 2004 - Issue 13
Submit an article Journal homepage
71
Views
225
CrossRef citations to date
0
Altmetric
Cell Growth and Development

Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity

Davide Danovi1 Department of Experimental Oncology, European Institute of Oncology, 20141Milan
,
Erik Meulmeester2 Department of Molecular and Cell Biology, Leiden University Medical Center, 2300 RALeiden, The Netherlands
,
Diego Pasini1 Department of Experimental Oncology, European Institute of Oncology, 20141Milan
,
Domenico Migliorini1 Department of Experimental Oncology, European Institute of Oncology, 20141Milan
,
Maria Capra1 Department of Experimental Oncology, European Institute of Oncology, 20141Milan;3 FIRC Institute of Molecular Oncology, 20139Milan, Italy
,
Ruth Frenk2 Department of Molecular and Cell Biology, Leiden University Medical Center, 2300 RALeiden, The Netherlands
,
Petra de Graaf2 Department of Molecular and Cell Biology, Leiden University Medical Center, 2300 RALeiden, The Netherlands
,
Sarah Francoz4 Unit of Molecular Embryology, Free University of Brussels, B-6041Gosselies;5 Laboratory of Molecular Cancer Biology, Flanders Interuniversity Institute for Biotechnology, B-9052Ghent, Belgium
,
Patrizia Gasparini1 Department of Experimental Oncology, European Institute of Oncology, 20141Milan;3 FIRC Institute of Molecular Oncology, 20139Milan, Italy
,
Alberto Gobbi1 Department of Experimental Oncology, European Institute of Oncology, 20141Milan;3 FIRC Institute of Molecular Oncology, 20139Milan, Italy
,
Kristian Helin1 Department of Experimental Oncology, European Institute of Oncology, 20141Milan;3 FIRC Institute of Molecular Oncology, 20139Milan, Italy
,
Pier Giuseppe Pelicci1 Department of Experimental Oncology, European Institute of Oncology, 20141Milan;3 FIRC Institute of Molecular Oncology, 20139Milan, Italy
,
Aart G. Jochemsen2 Department of Molecular and Cell Biology, Leiden University Medical Center, 2300 RALeiden, The Netherlands
&
Jean-Christophe Marine1 Department of Experimental Oncology, European Institute of Oncology, 20141Milan;5 Laboratory of Molecular Cancer Biology, Flanders Interuniversity Institute for Biotechnology, B-9052Ghent, BelgiumCorrespondence[email protected]
 show all
Pages 5835-5843 | Received 02 Oct 2003, Accepted 12 Mar 2004, Published online: 27 Mar 2023

Citations (225)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (14)

Suliman A Alsagaby. (2022) Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma. International Journal of Nanomedicine 17, pages 2261-2281.
Read now
Xiaolei Yao, Hui Shen, Qinghua Peng & Jingsheng Yu. (2021) TP53/miR-129/MDM2/4/TP53 feedback loop modulates cell proliferation and apoptosis in retinoblastoma. Cell Cycle 20:5-6, pages 603-615.
Read now
De-Ming Zhao, Yu-E Diao & Qing Xu. (2020) Association of MDM4 Gene rs4245739 Polymorphism with the Risk and Clinical Characteristics of Colorectal Cancer in a Chinese Han Population. Pharmacogenomics and Personalized Medicine 13, pages 673-678.
Read now
Jae-Sun Shin, Ji-Hyang Ha, Dong-Hwa Lee, Kyoung-Seok Ryu, Kwang-Hee Bae, Byoung Chul Park, Sung Goo Park, Gwan-Su Yi & Seung-Wook Chi. (2015) Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition. Cell Cycle 14:4, pages 533-543.
Read now
Anne-Sophie Tournillon, Ignacio López, Laurence Malbert-Colas, Nadia Naski, Vanesa Olivares-Illana & Robin Fåhraeus. (2015) The alternative translated MDMXp60 isoform regulates MDM2 activity. Cell Cycle 14:3, pages 449-458.
Read now
Swethajit Biswas, Emma Killick, Aart G Jochemsen & John Lunec. (2014) The clinical development of p53-reactivating drugs in sarcomas – charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins. Expert Opinion on Investigational Drugs 23:5, pages 629-645.
Read now
Ezharul Hoque Chowdhury. (2011) Strategies for tumor-directed delivery of siRNA. Expert Opinion on Drug Delivery 8:3, pages 389-401.
Read now
Sarah De Clercq, Agnieszka Gembarska, Geertrui Denecker, Marion Maetens, Michael Naessens, Katharina Haigh, Jody J. Haigh & Jean-Christophe Marine. (2010) Widespread Overexpression of Epitope-Tagged Mdm4 Does Not Accelerate Tumor Formation In Vivo. Molecular and Cellular Biology 30:22, pages 5394-5405.
Read now
Kelly R. Miller, Kevin Kelley, Rebecca Tuttle & Steven Berberich. (2010) HdmX overexpression inhibits oncogene induced cellular senescence. Cell Cycle 9:16, pages 3396-3402.
Read now
John P Alao. (2009) The ATM regulated DNA damage response pathway as a chemo- and radiosensitisation target. Expert Opinion on Drug Discovery 4:5, pages 495-505.
Read now
Daniele M. Gilkes, Yu Pan, Domenico Coppola, Timothy Yeatman, Gary W. Reuther & Jiandong Chen. (2008) Regulation of MDMX Expression by Mitogenic Signaling. Molecular and Cellular Biology 28:6, pages 1999-2010.
Read now
Zdenka Matijasevic, Heather A. Steinman, Kathleen Hoover & Stephen N. Jones. (2008) MdmX Promotes Bipolar Mitosis To Suppress Transformation and Tumorigenesis in p53-Deficient Cells and Mice. Molecular and Cellular Biology 28:4, pages 1265-1273.
Read now
Tamara Terzian, Yongxing Wang, Carolyn S. Van Pelt, Neil F. Box, Elisabeth L. Travis & Guillermina Lozano. (2007) Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development. Molecular and Cellular Biology 27:15, pages 5479-5485.
Read now
Koji Okamoto, Kenji Kashima, Yaron Pereg, Michiko Ishida, Satomi Yamazaki, Ayumi Nota, Amina Teunisse, Domenico Migliorini, Issay Kitabayashi, Jean-Christophe Marine, Carol Prives, Yosef Shiloh, Aart G. Jochemsen & Yoichi Taya. (2005) DNA Damage-Induced Phosphorylation of MdmX at Serine 367 Activates p53 by Targeting MdmX for Mdm2-Dependent Degradation. Molecular and Cellular Biology 25:21, pages 9608-9620.
Read now

Articles from other publishers (211)

Koki Ueda. (2023) Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies. Experimental Hematology 122, pages 10-18.
Crossref
Othman R. Alzahrani, Rashid Mir, Hanan E. Alatwi, Yousef M. Hawsawi, Amnah A. Alharbi, Abdulrahman H. Alessa, Elham Saleh Albalawi, Imadeldin Elfaki, Yousef Alalawi, Laila Moharam & Sabah H. El-Ghaiesh. (2023) Potential Impact of PI3K-AKT Signaling Pathway Genes, KLF-14, MDM4, miRNAs 27a, miRNA-196a Genetic Alterations in the Predisposition and Progression of Breast Cancer Patients. Cancers 15:4, pages 1281.
Crossref
Seyed Mohammad Ali Hashemi, Abdolvahab Moradi, Seyed Younes Hosseini, Hadi Razavi Nikoo, Taravat Bamdad, Mahboobeh Razmkhah, Jamal Sarvari & Alijan Tabarraei*. (2023) EBNA1 Upregulates P53-Inhibiting Genes in Burkitt's Lymphoma Cell Line. Reports of Biochemistry and Molecular Biology 11:4, pages 672-683.
Crossref
Marie Sebert, Stéphanie Gachet, Thierry Leblanc, Alix Rousseau, Olivier Bluteau, Rathana Kim, Raouf Ben Abdelali, Flore Sicre de Fontbrune, Loïc Maillard, Carèle Fedronie, Valentine Murigneux, Léa Bellenger, Naira Naouar, Samuel Quentin, Lucie Hernandez, Nadia Vasquez, Mélanie Da Costa, Pedro H. Prata, Lise Larcher, Marie de Tersant, Matthieu Duchmann, Anna Raimbault, Franck Trimoreau, Odile Fenneteau, Wendy Cuccuini, Nathalie Gachard, Nathalie Auger, Giulia Tueur, Maud Blanluet, Claude Gazin, Michèle Souyri, Francina Langa Vives, Aaron Mendez-Bermudez, Hélène Lapillonne, Etienne Lengline, Emmanuel Raffoux, Pierre Fenaux, Lionel Adès, Edouard Forcade, Charlotte Jubert, Carine Domenech, Marion Strullu, Bénédicte Bruno, Nimrod Buchbinder, Caroline Thomas, Arnaud Petit, Guy Leverger, Gérard Michel, Marina Cavazzana, Eliane Gluckman, Yves Bertrand, Nicolas Boissel, André Baruchel, Jean-Hugues Dalle, Emmanuelle Clappier, Eric Gilson, Ludovic Deriano, Sylvie Chevret, François Sigaux, Gérard Socié, Dominique Stoppa-Lyonnet, Hugues de Thé, Christophe Antoniewski, Dominique Bluteau, Régis Peffault de Latour & Jean Soulier. (2023) Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia. Cell Stem Cell 30:2, pages 153-170.e9.
Crossref
Yuqin Di, Xiaoqian Jing, Kunhua Hu, Xiangqiong Wen, Lvlan Ye, Xiang Zhang, Jiale Qin, Jinning Ye, Run Lin, Ziyang Wang & Weiling He. (2023) The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity. Drug Resistance Updates 66, pages 100909.
Crossref
Angelo Aguilar & Shaomeng Wang. (2022) Therapeutic Strategies to Activate p53. Pharmaceuticals 16:1, pages 24.
Crossref
Gabriela Mattevi Almeida, Ana Clara Castilho, Douglas Adamoski & Karin Braun-Prado. (2022) MDM4: What do we know about the association between its polymorphisms and cancer?. Medical Oncology 40:1.
Crossref
Hai Lin, Fengjie Sun, Tingting Li, Yihan Zhang, Xiaochun Guo, Ming Li, Min Liang, Xinke Zhou & Zhiyuan Fang. (2022) Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways. Cancer Chemotherapy and Pharmacology 90:6, pages 455-465.
Crossref
Rongmiao Zhou, Yan Li, Na Wang, Chaoxu Niu, Xi Huang, Shiru Cao & Xiangran Huo. (2022) MDM4 polymorphisms associated with the risk but not the prognosis of esophageal cancer in Cixian high‐incidence region from northern China . Asia-Pacific Journal of Clinical Oncology 18:5.
Crossref
Gregory R. Bean, Saleh Najjar, Sandra J. Shin, Elizabeth M. Hosfield, Jennifer L. Caswell-Jin, Anatoly Urisman, Kirk D. Jones, Yunn-Yi Chen & Gregor Krings. (2022) Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast. Modern Pathology 35:10, pages 1349-1361.
Crossref
Qinyan Song, Xiang-Qin Liu & Jan K. Rainey. (2022) The MDMX acidic domain competes with the p53 transactivation domain for MDM2 N-terminal domain binding. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1869:10, pages 119319.
Crossref
Javier Octavio Mejía-Hernández, Dinesh Raghu, Franco Caramia, Nicholas Clemons, Kenji Fujihara, Thomas Riseborough, Amina Teunisse, Aart G. Jochemsen, Lars Abrahmsén, Giovanni Blandino, Andrea Russo, Cristina Gamell, Stephen B. Fox, Catherine Mitchell, Elena A. Takano, David Byrne, Panimaya Jeffreena Miranda, Reem Saleh, Heather Thorne, Shahneen Sandhu, Scott G. Williams, Simon P. Keam, Ygal Haupt & Sue Haupt. (2022) Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status. Cancers 14:16, pages 3947.
Crossref
Karim M. ElSawy, Fahad M. Alminderej, Chandra S. Verma & Leo S. D. Caves. (2022) Activating the p53 anti-cancer pathway by targeting the MDM2/MDMX dimer interface with short peptide segments: a computational peptide design experiment. Molecular Systems Design & Engineering 7:8, pages 996-1006.
Crossref
Karla Gisel Calderon-González, Ixaura Medina-Medina, Lucia Haronikova, Lenka Hernychova, Ondrej Bonczek, Lukas Uhrik, Vaclav Hrabal, Borivoj Vojtesek, Robin Fahraeus, Jesús Hernández-Monge & Vanesa Olivares-Illana. (2022) Cryptic in vitro ubiquitin ligase activity of HDMX towards p53 is probably regulated by an induced fit mechanism . Bioscience Reports 42:7.
Crossref
Champak Chatterjee & Sumeet K. Singh. (2022) Peptide and protein chemistry approaches to study the tumor suppressor protein p53. Organic & Biomolecular Chemistry 20:28, pages 5500-5509.
Crossref
Shiyan Zhang, Ziqin Yan, Yafang Li, Yang Gong, Xilin Lyu, Jianfeng Lou, Daizhou Zhang, Xiangjing Meng & Yujun Zhao. (2022) Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells. Journal of Medicinal Chemistry 65:8, pages 6207-6230.
Crossref
Heng Jiang, Jing Luo & Hetian Lei. (2022) The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review. Experimental Eye Research 217, pages 108910.
Crossref
Qinyan Song, Xiang-Qin Liu & Jan K. Rainey. (2022) 1H, 15N and 13C backbone resonance assignments of the acidic domain of the human MDMX protein. Biomolecular NMR Assignments 16:1, pages 171-178.
Crossref
Che-Pei Kung & Jason D. Weber. (2022) It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy. Frontiers in Cell and Developmental Biology 10.
Crossref
Raman Akinyanju Lawal, Uma P. Arora & Beth L. Dumont. (2021) Selection shapes the landscape of functional variation in wild house mice. BMC Biology 19:1.
Crossref
Daniil R. Bazanov, Nikolay V. Pervushin, Egor V. Savin, Michael D. Tsymliakov, Anita I. Maksutova, Sergey E. Sosonyuk, Gelina S. Kopeina & Natalia A. Lozinskaya. (2021) Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors. Medicinal Chemistry Research 30:12, pages 2216-2227.
Crossref
Yan-Ling Chen, Zi-Mu Zhang, Xiao-Lu Li, Yan-Fang Tao, Shui-Yan Wu, Fang Fang, Yi Xie, Xin-Mei Liao, Gen Li, Di Wu, Hai-Rong Wang, Ran Zuo, Hai-Bo Cao, Jing-Jing Pan, Juan-Juan Yu, Zheng Zhang, Xin-Ran Chu, Yong-Ping Zhang, Chen-Xi Feng, Jian-Wei Wang, Jun Lu, Shao-Yan Hu, Zhi-Heng Li & Jian Pan. (2021) MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1. Oncology Letters 22:6.
Crossref
Antonino Lauria, Gabriele La Monica, Carla Gentile, Giuseppe Mannino, Annamaria Martorana & Daniele Peri. (2021) Identification of biological targets through the correlation between cell line chemosensitivity and protein expression pattern. Drug Discovery Today 26:10, pages 2431-2438.
Crossref
Shiyan Zhang, Jianfeng Lou, Yafang Li, Feilong Zhou, Ziqin Yan, Xilin Lyu & Yujun Zhao. (2021) Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions. Journal of Medicinal Chemistry 64:15, pages 10621-10640.
Crossref
Kimiyoshi Yano, Ryou-u Takahashi, Bunsyo Shiotani, Junko Abe, Tomoki Shidooka, Yuki Sudo, Yusuke Yamamoto, Shisei Kan, Hiroki Sakagami & Hidetoshi Tahara. (2021) PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA. Journal of Biological Chemistry 297:1, pages 100882.
Crossref
Dennis M. Timmerman, Tessa L. Remmers, Sanne Hillenius & Leendert H. J. Looijenga. (2021) Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells—Relevance for Understanding (Germ Cell) Tumorigenesis. International Journal of Molecular Sciences 22:10, pages 5377.
Crossref
Dehua Yu, Zhiyuan Xu, Xiangdong Cheng & Jiangjiang Qin. (2021) The role of miRNAs in MDMX‐p53 interplay. Journal of Evidence-Based Medicine 14:2, pages 152-160.
Crossref
Grégoire J.-B. Philippe, Anna Mittermeier, Nicole Lawrence, Yen-Hua Huang, Nicholas D. Condon, Alexander Loewer, David J. Craik & Sónia T. Henriques. (2021) Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells. ACS Chemical Biology 16:2, pages 414-428.
Crossref
Rossella Pellegrino, Abhishek Thavamani, Diego F. Calvisi, Jan Budczies, Ariane Neumann, Robert Geffers, Jasmin Kroemer, Damaris Greule, Peter Schirmacher, Alfred Nordheim & Thomas Longerich. (2021) Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC. Cancers 13:2, pages 199.
Crossref
Zhixia Zhou, Qi Gong, Zhijuan Lin, Yin Wang, Mengkun Li, Lu Wang, Hongfei Ding & Peifeng Li. (2020) Emerging Roles of SRSF3 as a Therapeutic Target for Cancer. Frontiers in Oncology 10.
Crossref
Monika Štětková, Kateřina Growková, Petr Fojtík, Barbora Valčíková, Veronika Palušová, Amandine Verlande, Radek Jorda, Vladimír Kryštof, Václav Hejret, Panagiotis Alexiou, Vladimír Rotrekl & Stjepan Uldrijan. (2020) CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells. Cell Death & Disease 11:9.
Crossref
Haishan Zhang, Jia Wang, Aolin Du & Yang Li. (2020) MiR-483-3p inhibition ameliorates myocardial ischemia/reperfusion injury by targeting the MDM4/p53 pathway. Molecular Immunology 125, pages 9-14.
Crossref
De-Hua Yu, Zhi-Yuan Xu, Shaowei Mo, Li Yuan, Xiang-Dong Cheng & Jiang-Jiang Qin. (2020) Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges. Frontiers in Oncology 10.
Crossref
Leiwei Jiang, Shibo Huang, Jieqiong Wang, Yiwei Zhang, Yuqing Xiong, Shelya X. Zeng & Hua Lu. (2020) Inactivating p53 is essential for nerve growth factor receptor to promote melanoma-initiating cell-stemmed tumorigenesis. Cell Death & Disease 11:7.
Crossref
Qian Hao, Yajie Chen & Xiang Zhou. (2020) The Janus Face of p53-Targeting Ubiquitin Ligases. Cells 9:7, pages 1656.
Crossref
Yuan Fang, Guochao Liao & Bin Yu. (2020) Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives. Acta Pharmaceutica Sinica B 10:7, pages 1253-1278.
Crossref
Kai Wohlberedt, Ina Klusmann, Polina K. Derevyanko, Kester Henningsen, Josephine Ann Mun Yee Choo, Valentina Manzini, Anna Magerhans, Celeste Giansanti, Christine M. Eischen, Aart G. Jochemsen & Matthias Dobbelstein. (2020) Mdm4 supports DNA replication in a p53-independent fashion. Oncogene 39:25, pages 4828-4843.
Crossref
Jerson L. Silva, Carolina G. S. Lima, Luciana P. Rangel, Giulia D. S. Ferretti, Fernanda P. Pauli, Ruan C. B. Ribeiro, Thais de B. da Silva, Fernando C. da Silva & Vitor F. Ferreira. (2020) Recent Synthetic Approaches towards Small Molecule Reactivators of p53. Biomolecules 10:4, pages 635.
Crossref
Chong Gao, Gu Xiao, Alessandra Piersigilli, Jiangtao Gou, Olorunseun Ogunwobi & Jill Bargonetti. (2019) Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Research 21:1.
Crossref
Mathias L. Heltberg, Sheng-hong Chen, Alba Jiménez, Ashwini Jambhekar, Mogens H. Jensen & Galit Lahav. (2019) Inferring Leading Interactions in the p53/Mdm2/Mdmx Circuit through Live-Cell Imaging and Modeling. Cell Systems 9:6, pages 548-558.e5.
Crossref
Ammad Ahmad Farooqi, Marc de la Roche, Mustafa B.A. Djamgoz & Zahid H. Siddik. (2019) Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Seminars in Cancer Biology 58, pages 65-79.
Crossref
Lan Cao, Ahmed Basudan, Matthew J. Sikora, Amir Bahreini, Nilgun Tasdemir, Kevin M. Levine, Rachel C. Jankowitz, Priscilla F. McAuliffe, David Dabbs, Sue Haupt, Ygal Haupt, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich & Jennifer M. Atkinson. (2019) Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Letters 461, pages 21-30.
Crossref
Chong Gao, Gu Xiao & Jill Bargonetti. (2019) Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. Oncotarget 10:49, pages 5007-5010.
Crossref
Tao Liu, Hailong Zhang, Sha Yi, Lubing Gu & Muxiang Zhou. (2019) Mutual regulation of MDM 4 and TOP 2A in cancer cell proliferation . Molecular Oncology 13:5, pages 1047-1058.
Crossref
Marcus Bauer, Eva Johanna Kantelhardt, Thorsten Stiewe, Andrea Nist, Marco Mernberger, Katharina Politt, Volker Hanf, Tilmann Lantzsch, Christoph Uleer, Susanne Peschel, Jutta John, Jörg Buchmann, Edith Weigert, Karl-Friedrich Bürrig, Claudia Wickenhauser, Christoph Thomssen, Frank Bartel & Martina Vetter. (2019) Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients . Oncotarget 10:20, pages 1975-1992.
Crossref
Sue Haupt, Javier Octavio Mejía-Hernández, Reshma Vijayakumaran, Simon P Keam & Ygal Haupt. (2019) The long and the short of it: the MDM4 tail so far. Journal of Molecular Cell Biology 11:3, pages 231-244.
Crossref
Jill L. O. de Jong. (2019) Splicing up hematopoietic development. Blood 133:8, pages 770-771.
Crossref
Shanshan Yu, Tao JiangDanna JiaYunqiao HanFei LiuYuwen HuangZhen QuYuntong Zhao, Jiayi TuYuexia LvJingzhen LiXuebin HuZhaojing LuShanshan HanYayun QinXiliang LiuShanglun XieQing K. WangZhaohui TangDaji Luo & Mugen Liu. (2019) BCAS2 is essential for hematopoietic stem and progenitor cell maintenance during zebrafish embryogenesis. Blood 133:8, pages 805-815.
Crossref
Mamiko Imanishi, Yoshiyuki Yamamoto, Xiaoxuan Wang, Akinori Sugaya, Mitsuaki Hirose, Shinji Endo, Yukikazu Natori, Kenji Yamato & Ichinosuke Hyodo. (2019) Augmented antitumor activity of 5‐fluorouracil by double knockdown of MDM 4 and MDM 2 in colon and gastric cancer cells . Cancer Science 110:2, pages 639-649.
Crossref
Yan Zhu, Herui Wang & Asha Thuraisamy. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy 243 266 .
Tatsuya Kawase, Yu Chen & Rieko Ohki. 2019. Heat Shock Proteins in Signaling Pathways. Heat Shock Proteins in Signaling Pathways 253 272 .
Matthias G.J. Baud, Matthias R. Bauer, Lorena Verduci, Felix A. Dingler, Ketan J. Patel, Deeptee Horil Roy, Andreas C. Joerger & Alan R. Fersht. (2018) Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. European Journal of Medicinal Chemistry 152, pages 101-114.
Crossref
Harman Chopra, Zara Khan, Jamie Contreras, Herui Wang, Abanob Sedrak & Yan Zhu. (2017) Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells. Oncotarget 9:5, pages 6270-6281.
Crossref
Taro NoguchiTaro Noguchi. 2018. Development of Chemistry-Based Screening Platform for Access to Mirror-Image Library of Natural Products. Development of Chemistry-Based Screening Platform for Access to Mirror-Image Library of Natural Products 11 47 .
Janaki Parameswaran & Barbara Burtness. 2018. Molecular Determinants of Head and Neck Cancer. Molecular Determinants of Head and Neck Cancer 249 274 .
Julia Abramowitz, Tzahi Neuman, Riki Perlman & Dina Ben-Yehuda. (2017) Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia. BMC Medical Genomics 10:1.
Crossref
Neeraj K. Aryal, Amanda R. Wasylishen, Vinod Pant, Maurisa Riley-Croce & Guillermina Lozano. (2017) Loss of digestive organ expansion factor ( Diexf) reveals an essential role during murine embryonic development that is independent of p53 . Oncotarget 8:61, pages 103996-104006.
Crossref
Mariateresa Giustiniano, Simona Daniele, Sveva Pelliccia, Valeria La Pietra, Deborah Pietrobono, Diego Brancaccio, Sandro Cosconati, Anna Messere, Stefano Giuntini, Linda Cerofolini, Marco Fragai, Claudio Luchinat, Sabrina Taliani, Giuseppe La Regina, Federico Da Settimo, Romano Silvestri, Claudia Martini, Ettore Novellino & Luciana Marinelli. (2017) Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure–Activity Relationship Studies and Pharmacological Activity. Journal of Medicinal Chemistry 60:19, pages 8115-8130.
Crossref
Daniel Nguyen, Wenjuan Liao, Shelya X. Zeng & Hua Lu. (2017) Reviving the guardian of the genome: Small molecule activators of p53. Pharmacology & Therapeutics 178, pages 92-108.
Crossref
Lasse Staby, Charlotte O'Shea, Martin Willemoës, Frederik Theisen, Birthe B. Kragelund & Karen Skriver. (2017) Eukaryotic transcription factors: paradigms of protein intrinsic disorder. Biochemical Journal 474:15, pages 2509-2532.
Crossref
Han Zhao, Yu-Zhuo Xie, Rui Xing, Ming Sun, Feng Chi & Yue-Can Zeng. (2017) MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin. Cellular Oncology 40:4, pages 357-365.
Crossref
Vinod Pant, Connie A. Larsson, Neeraj Aryal, Shunbin Xiong, M. James You, Alfonso Quintas-Cardama & Guillermina Lozano. (2017) Tumorigenesis promotes Mdm4-S overexpression. Oncotarget 8:16, pages 25837-25847.
Crossref
Shunbin Xiong, Vinod Pant, Yun Zhang, Neeraj K Aryal, M James You, Donna Kusewitt & Guillermina Lozano. (2017) The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. The Journal of Pathology 241:4, pages 501-510.
Crossref
A-S Tournillon, I López, L Malbert-Colas, S Findakly, N Naski, V Olivares-Illana, K Karakostis, B Vojtesek, K Nylander & R Fåhraeus. (2016) p53 binds the mdmx mRNA and controls its translation. Oncogene 36:5, pages 723-730.
Crossref
Sue Haupt, Reshma Vijayakumaran, Panimaya Jeffreena Miranda, Andrew Burgess, Elgene Lim & Ygal Haupt. (2017) The role of MDM2 and MDM4 in breast cancer development and prevention. Journal of Molecular Cell Biology 9:1, pages 53-61.
Crossref
I.R. Hardcastle. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III 154 201 .
Sheng-hong Chen & Galit Lahav. (2016) Two is better than one; toward a rational design of combinatorial therapy. Current Opinion in Structural Biology 41, pages 145-150.
Crossref
Alessandra Fierabracci & Marsha Pellegrino. (2016) The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target. International Journal of Molecular Sciences 17:12, pages 1975.
Crossref
Z Matijasevic, A Krzywicka-Racka, G Sluder, J Gallant & S N Jones. (2016) The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells. Oncogenesis 5:10, pages e262-e262.
Crossref
Danielly C.F. Costa, Guilherme A.P. de Oliveira, Elio A. Cino, Iaci N. Soares, Luciana P. Rangel & Jerson L. Silva. (2016) Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?. Cold Spring Harbor Perspectives in Biology 8:10, pages a023614.
Crossref
Ming-Jie Wang, Yong-Jun Luo, Zhi-Yong Shi, Xiao-Liang Xu, Guo-Liang Yao, Rui-Ping Liu & Hui Zhao. (2016) The associations between MDM4 gene polymorphisms and cancer risk. Oncotarget 7:34, pages 55611-55623.
Crossref
Xin Han, L. Jeffrey Medeiros, Yu Helen Zhang, M. James You, Michael Andreeff, Marina Konopleva & Carlos E. Bueso-Ramos. (2016) High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia 16, pages S30-S38.
Crossref
Liv B. Gansmo, Merete Bjørnslett, Mari Kyllesø Halle, Helga B. Salvesen, Anne Dørum, Einar Birkeland, Kristian Hveem, Pål Romundstad, Lars Vatten, Per Eystein Lønning & Stian Knappskog. (2016) The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer. Tumor Biology 37:8, pages 10697-10702.
Crossref
Jean-Christophe Marine & Aart G. Jochemsen. (2016) MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond. Cold Spring Harbor Perspectives in Medicine 6:7, pages a026237.
Crossref
JINQIAN LIANG, DAN XING, ZHENG LI, JIANXIONG SHEN, HONG ZHAO & SHUGANG LI. (2016) TRIM59 is upregulated and promotes cell proliferation and migration in human osteosarcoma. Molecular Medicine Reports 13:6, pages 5200-5206.
Crossref
Orit Karni-SchmidtMaria LokshinCarol Prives. (2016) The Roles of MDM2 and MDMX in Cancer. Annual Review of Pathology: Mechanisms of Disease 11:1, pages 617-644.
Crossref
Xi WeiShaofang WuTanjing SongLihong ChenMing GaoWade Borcherds, Gary W. Daughdrill & Jiandong Chen. (2016) Secondary interaction between MDMX and p53 core domain inhibits p53 DNA binding. Proceedings of the National Academy of Sciences 113:19.
Crossref
Wendy M. Swetzig, Jianmin Wang & Gokul M. Das. (2016) Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. Oncotarget 7:13, pages 16049-16069.
Crossref
Ewa D. Micewicz, Shantanu Sharma, Alan J. Waring, Hai T. Luong, William H. McBride & Piotr Ruchala. (2015) Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation. International Journal of Peptide Research and Therapeutics 22:1, pages 67-81.
Crossref
Mehrnoosh Tashakori, Yun Zhang, Shunbin Xiong, M. James You & Guillermina Lozano. (2016) p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis . Molecular Cancer Research 14:1, pages 56-65.
Crossref
Charlotte KY Ng, Luciano G Martelotto, Arnaud Gauthier, Huei-Chi Wen, Salvatore Piscuoglio, Raymond S Lim, Catherine F Cowell, Paul M Wilkerson, Patty Wai, Daniel N Rodrigues, Laurent Arnould, Felipe C Geyer, Silvio E Bromberg, Magali Lacroix-Triki, Frederique Penault-Llorca, Sylvia Giard, Xavier Sastre-Garau, Rachael Natrajan, Larry Norton, Paul H Cottu, Britta Weigelt, Anne Vincent-Salomon & Jorge S Reis-Filho. (2015) Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biology 16:1.
Crossref
Liv B. Gansmo, Pål Romundstad, Einar Birkeland, Kristian Hveem, Lars Vatten, Stian Knappskog & Per Eystein Lønning. (2015) MDM4 SNP34091 (rs4245739) and its effect on breast‐, colon‐, lung‐, and prostate cancer risk . Cancer Medicine 4:12, pages 1901-1907.
Crossref
Michael Dewaele, Tommaso Tabaglio, Karen Willekens, Marco Bezzi, Shun Xie Teo, Diana H.P. Low, Cheryl M. Koh, Florian Rambow, Mark Fiers, Aljosja Rogiers, Enrico Radaelli, Muthafar Al-Haddawi, Soo Yong Tan, Els Hermans, Frederic Amant, Hualong Yan, Manikandan Lakshmanan, Ratnacaram Chandrahas Koumar, Soon Thye Lim, Frederick A. Derheimer, Robert M. Campbell, Zahid Bonday, Vinay Tergaonkar, Mark Shackleton, Christine Blattner, Jean-Christophe Marine & Ernesto Guccione. (2015) Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth. Journal of Clinical Investigation 126:1, pages 68-84.
Crossref
S Haupt, D Buckley, J-MB Pang, J Panimaya, P J Paul, C Gamell, E A Takano, Y Ying Lee, S Hiddingh, T-M Rogers, A F A S Teunisse, M J Herold, J-C Marine, S B Fox, A Jochemsen & Y Haupt. (2015) Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death & Disease 6:7, pages e1821-e1821.
Crossref
Chen Xie, Wei Chen, Mengdie Zhang, Qiuxian Cai, Weiyi Xu, Xiaodi Li & Songshan Jiang. (2015) MDM4 regulation by the let-7 miRNA family in the DNA damage response of glioma cells. FEBS Letters 589:15, pages 1958-1965.
Crossref
Kathleen I. Pishas, Alaknanda Adwal, Susan J. Neuhaus, Mark T. Clayer, Gelareh Farshid, Alexander H. Staudacher & David F. Callen. (2015) XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Scientific Reports 5:1.
Crossref
A M Carrillo, A Bouska, M P Arrate & C M Eischen. (2014) Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene 34:7, pages 846-856.
Crossref
Elin Möllerström, Bertil Rydenhag, Daniel Andersson, Isabell Lebkuechner, Till B. Puschmann, Meng Chen, Ulrika Wilhelmsson, Anders Ståhlberg, Kristina Malmgren & Milos Pekny. (2014) Classification of Subpopulations of Cells Within Human Primary Brain Tumors by Single Cell Gene Expression Profiling. Neurochemical Research 40:2, pages 336-352.
Crossref
Ket Hing Chong, Sandhya Samarasinghe & Don Kulasiri. (2015) Mathematical modelling of p53 basal dynamics and DNA damage response. Mathematical Biosciences 259, pages 27-42.
Crossref
Qiong Yu, Yan Li, Kun Mu, Zhishuang Li, Qingyong Meng, Xiaojuan Wu, Yan Wang & Li Li. (2014) Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagnostic Pathology 9:1.
Crossref
Mitsuaki Hirose, Kenji Yamato, Shinji Endo, Rie Saito, Takunori Ueno, Sachiko Hirai, Hideo Suzuki, Masato Abei, Yukikazu Natori & Ichinosuke Hyodo. (2014) MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation. Oncoscience 1:12, pages 830-843.
Crossref
Suzanne Lam, Eliza Wiercinska, Amina F. A. S. Teunisse, Kirsten Lodder, Peter ten Dijke & Aart G. Jochemsen. (2014) Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene. Breast Cancer Research and Treatment 148:1, pages 7-18.
Crossref
Galina Selivanova. (2014) Wild type p53 reactivation: From lab bench to clinic. FEBS Letters 588:16, pages 2628-2638.
Crossref
Aishwarya G. Jacob, Ravi K. Singh, Daniel F. Comiskey, Matthew F. Rouhier, Fuad Mohammad, Thomas W. Bebee & Dawn S. Chandler. (2014) Stress-Induced Alternative Splice Forms of MDM2 and MDMX Modulate the p53-Pathway in Distinct Ways. PLoS ONE 9:8, pages e104444.
Crossref
BYUNG JOO LEE, JIN HYOUNG KIM, DONG HYUN JO, KYU-WON KIM, YOUNG SUK YU & JEONG HUN KIM. (2014) Nuclear expression of p53 in mature tumor endothelium of retinoblastoma. Oncology Reports 32:2, pages 801-807.
Crossref
Laura A. Tollini, Aiwen Jin, Jikyoung Park & Yanping Zhang. (2014) Regulation of p53 by Mdm2 E3 Ligase Function Is Dispensable in Embryogenesis and Development, but Essential in Response to DNA Damage. Cancer Cell 26:2, pages 235-247.
Crossref
Xin Yu, Sumana Narayanan, Alexei Vazquez & Darren R. Carpizo. (2014) Small molecule compounds targeting the p53 pathway: are we finally making progress?. Apoptosis 19:7, pages 1055-1068.
Crossref
Christine M. Eischen & Guillermina Lozano. (2014) The Mdm Network and Its Regulation of p53 Activities: A Rheostat of Cancer Risk. Human Mutation 35:6, pages 728-737.
Crossref
Kathryn T. Bieging, Stephano Spano Mello & Laura D. Attardi. (2014) Unravelling mechanisms of p53-mediated tumour suppression. Nature Reviews Cancer 14:5, pages 359-370.
Crossref
Martin L. Read, Robert I. Seed, Jim C.W. Fong, Bhavika Modasia, Gavin A. Ryan, Rachel J Watkins, Teresa Gagliano, Vicki E. Smith, Anna L. Stratford, Perkin K Kwan, Neil Sharma, Olivia M. Dixon, John C. Watkinson, Kristien Boelaert, Jayne A. Franklyn, Andrew S. Turnell & Christopher J. McCabe. (2014) The PTTG1-Binding Factor (PBF/PTTG1IP) Regulates p53 Activity in Thyroid Cells. Endocrinology 155:4, pages 1222-1234.
Crossref
Rie Takahashi, Svetomir N. Markovic & Heidi J. Scrable. (2014) Dominant Effects of Δ40p53 on p53 Function and Melanoma Cell Fate. Journal of Investigative Dermatology 134:3, pages 791-800.
Crossref
Ban Xiong Tan, Kian Hoe Khoo, Tit Meng Lim & David Philip Lane. (2013) High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia. Oncotarget 5:4, pages 933-943.
Crossref
Nagakumar Bharatham, Kavitha Bharatham, Anang A. Shelat & Donald Bashford. (2014) Ligand Binding Mode Prediction by Docking: Mdm2/Mdmx Inhibitors as a Case Study. Journal of Chemical Information and Modeling 54:2, pages 648-659.
Crossref
Jing Xia & Weixiong Zhang. (2014) MicroRNAs in normal and psoriatic skin. Physiological Genomics 46:4, pages 113-122.
Crossref
Andreas K. Hock & Karen H. Vousden. (2014) The role of ubiquitin modification in the regulation of p53. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1843:1, pages 137-149.
Crossref
Ian R. Hardcastle. 2014. Cancer Drug Design and Discovery. Cancer Drug Design and Discovery 391 426 .
Kazushi Inoue & Elizabeth A. Fry. 2014. Mutant p53 and MDM2 in Cancer. Mutant p53 and MDM2 in Cancer 17 40 .
Steven J. Berberich. 2014. Mutant p53 and MDM2 in Cancer. Mutant p53 and MDM2 in Cancer 263 280 .
P E Lønning & S Knappskog. (2013) Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene 32:46, pages 5315-5330.
Crossref
Xiaowen Wang, Ping Sheng, Xingzhong Guo, Junyu Wang, Lijun Hou, Guohan Hu, Chun Luo, Yan Dong & Yicheng Lu. (2013) Identification and expression of a novel MDM4 splice variant in human glioma. Brain Research 1537, pages 260-266.
Crossref
Taro Noguchi, Shinya Oishi, Kaori Honda, Yasumitsu Kondoh, Tamio Saito, Tatsuhiko Kubo, Masato Kaneda, Hiroaki Ohno, Hiroyuki Osada & Nobutaka Fujii. (2013) Affinity-based screening of MDM2/MDMX–p53 interaction inhibitors by chemical array: Identification of novel peptidic inhibitors. Bioorganic & Medicinal Chemistry Letters 23:13, pages 3802-3805.
Crossref
Keiko Tsuganezawa, Yukari Nakagawa, Miki Kato, Shigenao Taruya, Fumio Takahashi, Morio Endoh, Rei Utata, Masumi Mori, Naoko Ogawa, Teruki Honma, Shigeyuki Yokoyama, Yoshinobu Hashizume, Masaaki Aoki, Takuma Kasai, Takanori Kigawa, Hirotatsu Kojima, Takayoshi Okabe, Tetsuo Nagano & Akiko Tanaka. (2013) A Fluorescent-Based High-Throughput Screening Assay for Small Molecules That Inhibit the Interaction of MdmX with p53. SLAS Discovery 18:2, pages 191-198.
Crossref
Mark Wade, Yao-Cheng Li & Geoffrey M. Wahl. (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Reviews Cancer 13:2, pages 83-96.
Crossref
Kareem Khoury, Tad A. Holak & Alexander Dömling. 2013. Protein-Protein Interactions in Drug Discovery. Protein-Protein Interactions in Drug Discovery 129 163 .
Vera V. Grinkevich, Andreas Warnecke & Galina Selivanova. 2013. p53 in the Clinics. p53 in the Clinics 231 255 .
Anna R. McCarthy & Sonia Lain. 2013. p53 in the Clinics. p53 in the Clinics 209 229 .
Ling Liu, Lei Fan, Cheng Fang, Zhi-Jian Zou, Shu Yang, Li-Na Zhang, Jian-Yong Li & Wei Xu. (2012) S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia. Cancer Science 103:12, pages 2056-2063.
Crossref
M Wade, Y C Li, A S Matani, S M G Braun, F Milanesi, L W Rodewald & G M Wahl. (2012) Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells. Oncogene 31:45, pages 4789-4797.
Crossref
Vasiliki Leventaki, Vladimir Rodic, Sheryl R. Tripp, Michael G. Bayerl, Sherrie L. Perkins, Phillip Barnette, Joshua D. Schiffman & Rodney R. Miles. (2012) TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. British Journal of Haematology 158:6, pages 763-771.
Crossref
Kristiaan Lenos, Anna M. Grawenda, Kirsten Lodder, Marieke L. Kuijjer, Amina F.A.S. Teunisse, Emmanouela Repapi, Lukasz F. Grochola, Frank Bartel, Pancras C.W. Hogendoorn, Peter Wuerl, Helge Taubert, Anne-Marie Cleton-Jansen, Gareth L. Bond & Aart G. Jochemsen. (2012) Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer. Cancer Research 72:16, pages 4074-4084.
Crossref
X Li, D Gilkes, B Li, Q Cheng, D Pernazza, H Lawrence, N Lawrence & J Chen. (2011) Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene 31:32, pages 3721-3732.
Crossref
Agnieszka Gembarska, Flavie Luciani, Clare Fedele, Elisabeth A Russell, Michael Dewaele, Stéphanie Villar, Aleksandra Zwolinska, Sue Haupt, Job de Lange, Dana Yip, James Goydos, Jody J Haigh, Ygal Haupt, Lionel Larue, Aart Jochemsen, Hubing Shi, Gatien Moriceau, Roger S Lo, Ghanem Ghanem, Mark Shackleton, Federico Bernal & Jean-Christophe Marine. (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine 18:8, pages 1239-1247.
Crossref
Bradford Graves, Thelma Thompson, Mingxuan Xia, Cheryl Janson, Christine Lukacs, Dayanand Deo, Paola Di Lello, David Fry, Colin Garvie, Kuo-Sen Huang, Lin Gao, Christian Tovar, Allen Lovey, Jutta Wanner & Lyubomir T. Vassilev. (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proceedings of the National Academy of Sciences 109:29, pages 11788-11793.
Crossref
Sharon I King, Colin A Purdie, Susan E Bray, Philip R Quinlan, Lee B Jordan, Alastair M Thompson & David W Meek. (2012) Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53mutation and poor clinical outcome. Breast Cancer Research 14:2.
Crossref
Dongsheng Pei, Yanping Zhang & Junnian Zheng. (2012) Regulation of p53: a collaboration between Mdm2 and MdmX. Oncotarget 3:3, pages 228-235.
Crossref
Hongping Yu, Erich M. Sturgis, Zhensheng Liu, Li-E. Wang, Qingyi Wei & Guojun Li. (2012) Modifying effect of MDM4 variants on risk of HPV16-associated squamous cell carcinoma of oropharynx. Cancer 118:6, pages 1684-1692.
Crossref
Frank Essmann & Klaus Schulze-Osthoff. (2012) Translational approaches targeting the p53 pathway for anti-cancer therapy. British Journal of Pharmacology 165:2, pages 328-344.
Crossref
Kristiaan Lenos, Job de Lange, Amina FAS Teunisse, Kirsten Lodder, Matty Verlaan-de Vries, Eliza Wiercinska, Marja JM van der Burg, Karoly Szuhai & Aart G Jochemsen. (2011) Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts. Molecular Cancer 10:1.
Crossref
C Spinnler, E Hedström, H Li, J de Lange, F Nikulenkov, A F A S Teunisse, M Verlaan-de Vries, V Grinkevich, A G Jochemsen & G Selivanova. (2011) Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. Cell Death & Differentiation 18:11, pages 1736-1745.
Crossref
Stanley Lipkowitz & Allan M. Weissman. (2011) RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nature Reviews Cancer 11:9, pages 629-643.
Crossref
Muyang Li & Wei Gu. (2011) A Critical Role for Noncoding 5S rRNA in Regulating Mdmx Stability. Molecular Cell 43:6, pages 1023-1032.
Crossref
Daniel Garcia, Matthew R. Warr, Carla P. Martins, Lamorna Brown Swigart, Emmanuelle Passegué & Gerard I. Evan. (2011) Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes & Development 25:16, pages 1746-1757.
Crossref
Hongbo Wang & Chunhong Yan. (2011) A Small-Molecule p53 Activator Induces Apoptosis through Inhibiting MDMX Expression in Breast Cancer Cells. Neoplasia 13:7, pages 611-IN6.
Crossref
Hongping Yu, Li-E Wang, Zhensheng Liu, Sheng Wei, Guojun Li, Erich M. Sturgis & Qingyi Wei. (2011) Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck. Pharmacogenetics and Genomics 21:7, pages 388-396.
Crossref
Brittany Cross, Lihong Chen, Qian Cheng, Baozong Li, Zhi-Min Yuan & Jiandong Chen. (2011) Inhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain. Journal of Biological Chemistry 286:18, pages 16018-16029.
Crossref
Domenico Migliorini, Sven Bogaerts, Dieter Defever, Rajesh Vyas, Geertrui Denecker, Enrico Radaelli, Aleksandra Zwolinska, Vanessa Depaepe, Tino Hochepied, William C. Skarnes & Jean-Christophe Marine. (2011) Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. Journal of Clinical Investigation 121:4, pages 1329-1343.
Crossref
Kathleen I. Pishas, Fares Al-Ejeh, Irene Zinonos, Raman Kumar, Andreas Evdokiou, Michael P. Brown, David F. Callen & Paul M. Neilsen. (2011) Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma. Clinical Cancer Research 17:3, pages 494-504.
Crossref
Hongbo Wang, Xujun Ma, Shumei Ren, John K. Buolamwini & Chunhong Yan. (2011) A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis. Molecular Cancer Therapeutics 10:1, pages 69-79.
Crossref
Kristiaan Lenos & Aart G. Jochemsen. (2011) Functions of MDMX in the Modulation of the p53-Response. Journal of Biomedicine and Biotechnology 2011, pages 1-14.
Crossref
Paul M. Neilsen, Kathleen I. Pishas, David F. Callen & David M. Thomas. (2011) Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma 2011, pages 1-17.
Crossref
Kareem Khoury, Grzegorz M. Popowicz, Tad A. Holak & Alexander Dömling. (2011) The p53-MDM2/MDMX axis – A chemotype perspective. MedChemComm 2:4, pages 246.
Crossref
Antonio Macchiarulo, Nicola Giacchè, Andrea Carotti, Fabiola Moretti & Roberto Pellicciari. (2011) Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4). MedChemComm 2:6, pages 455.
Crossref
I Goldstein, V Marcel, M Olivier, M Oren, V Rotter & P Hainaut. (2010) Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Therapy 18:1, pages 2-11.
Crossref
Jean-Christophe Marine. 2011. Cancer and Development. Cancer and Development 45 75 .
Lei Zhang, Hua Xiao, Scott Karlan, Hui Zhou, Jenny Gross, David Elashoff, David Akin, Xinmin Yan, David Chia, Beth Karlan & David T. Wong. (2010) Discovery and Preclinical Validation of Salivary Transcriptomic and Proteomic Biomarkers for the Non-Invasive Detection of Breast Cancer. PLoS ONE 5:12, pages e15573.
Crossref
Jessika Wynendaele, Anja Böhnke, Eleonora Leucci, Søren Jensby Nielsen, Irina Lambertz, Stefanie Hammer, Nadja Sbrzesny, Dana Kubitza, Anja Wolf, Elise Gradhand, Katharina Balschun, Ioana Braicu, Jalid Sehouli, Silvia Darb-Esfahani, Carsten Denkert, Christoph Thomssen, Steffen Hauptmann, Anders Lund, Jean-Christophe Marine & Frank Bartel. (2010) An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity . Cancer Research 70:23, pages 9641-9649.
Crossref
Federico Bernal, Mark Wade, Marina Godes, Tina N. Davis, David G. Whitehead, Andrew L. Kung, Geoffrey M. Wahl & Loren D. Walensky. (2010) A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53. Cancer Cell 18:5, pages 411-422.
Crossref
Flavia Pichiorri, Sung-Suk Suh, Alberto Rocci, Luciana De Luca, Cristian Taccioli, Ramasamy Santhanam, Wenchao Zhou, Don M. BensonJr.Jr., Craig Hofmainster, Hansjuerg Alder, Michela Garofalo, Gianpiero Di Leva, Stefano Volinia, Huey-Jen Lin, Danilo Perrotti, Michael Kuehl, Rami I. Aqeilan, Antonio Palumbo & Carlo M. Croce. (2010) RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development. Cancer Cell 18:4, pages 367-381.
Crossref
Edward J. Estlin, François Doz & Michael Dyer. 2010. Pediatric Hematology and Oncology. Pediatric Hematology and Oncology 306 318 .
Shunbin Xiong, Vinod Pant, Young-Ah Suh, Carolyn S. Van Pelt, Yongxing Wang, Yasmine A. Valentin-Vega, Sean M. Post & Guillermina Lozano. (2010) Spontaneous Tumorigenesis in Mice Overexpressing the p53-Negative Regulator Mdm4. Cancer Research 70:18, pages 7148-7154.
Crossref
Genglin Jin, Stephen Cook, Bo Cui, William C. Chen, Stephen T. Keir, Patrick Killela, Chunhui Di, Cathy A. Payne, Simon G. Gregory, Roger McLendon, Darell D. Bigner & Hai Yan. (2010) HDMX regulates p53 activity and confers chemoresistance to 3-Bis(2-chloroethyl)-1-nitrosourea. Neuro-Oncology 12:9, pages 956-966.
Crossref
Anna Phillips, Amina Teunisse, Suzanne Lam, Kirsten Lodder, Matthew Darley, Muhammad Emaduddin, Anja Wolf, Julia Richter, Job de Lange, Matty Verlaan-de Vries, Kristiaan Lenos, Anja Böhnke, Frank Bartel, Jeremy P. Blaydes & Aart G. Jochemsen. (2010) HDMX-L Is Expressed from a Functional p53-responsive Promoter in the First Intron of the HDMX Gene and Participates in an Autoregulatory Feedback Loop to Control p53 Activity. Journal of Biological Chemistry 285:38, pages 29111-29127.
Crossref
Zeinab Barekati, Ramin Radpour, Corina Kohler, Bei Zhang, Paolo Toniolo, Per Lenner, Qing Lv, Hong Zheng & Xiao Yan Zhong. (2010) Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations. Human Molecular Genetics 19:15, pages 2936-2946.
Crossref
Shreya Datta, Megan E. Bucks, Dipankar Koley, Pei Xin Lim & Sergey N. Savinov. (2010) Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system. Bioorganic & Medicinal Chemistry 18:16, pages 6099-6108.
Crossref
Lorenzo Montanaro, Maria Calienni, Sara Bertoni, Laura Rocchi, Pasquale Sansone, Gianluca Storci, Donatella Santini, Claudio Ceccarelli, Mario Taffurelli, Domenica Carnicelli, Maurizio Brigotti, Massimiliano Bonafè, Davide Treré & Massimo Derenzini. (2010) Novel Dyskerin-Mediated Mechanism of p53 Inactivation through Defective mRNA Translation. Cancer Research 70:11, pages 4767-4777.
Crossref
S Lam, K Lodder, A F A S Teunisse, M J W E Rabelink, M Schutte & A G Jochemsen. (2010) Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene 29:16, pages 2415-2426.
Crossref
Damon Reed, Ying Shen, Anang A. Shelat, Leggy A. Arnold, Antonio M. Ferreira, Fangyi Zhu, Nicholas Mills, David C. Smithson, Catherine A. Regni, Donald Bashford, Samantha A. Cicero, Brenda A. Schulman, Aart G. Jochemsen, R. Kiplin Guy & Michael A. Dyer. (2010) Identification and Characterization of the First Small Molecule Inhibitor of MDMX. Journal of Biological Chemistry 285:14, pages 10786-10796.
Crossref
Mei Liang, Xin Han, Saroj Vadhan-Raj, Martin Nguyen, Yu H Zhang, Michael Fernandez, Elias Drakos, Sergej N Konoplev, C Cameron Yin, Roberto N Miranda, Timothy J McDonnell, L Jeffrey Medeiros & Carlos E Bueso-Ramos. (2010) HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Modern Pathology 23:3, pages 381-391.
Crossref
David W. Meek & Ted R. Hupp. (2010) The regulation of MDM2 by multisite phosphorylation—Opportunities for molecular-based intervention to target tumours?. Seminars in Cancer Biology 20:1, pages 19-28.
Crossref
N Allende-Vega, A Sparks, D P Lane & M K Saville. (2009) MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene 29:3, pages 432-441.
Crossref
Ayeda Ayed & Theodore HuppJeremy Blaydes. 2010. p53. p53 85 99 .
Christopher J. Brown, Sonia Lain, Chandra S. Verma, Alan R. Fersht & David P. Lane. (2009) Awakening guardian angels: drugging the p53 pathway. Nature Reviews Cancer 9:12, pages 862-873.
Crossref
Melisa Bunderson-Schelvan, Amy K. Erbe, Corbin Schwanke & Mark A. Pershouse. (2009) Suppression of the mouse double minute 4 gene causes changes in cell cycle control in a human mesothelial cell line responsive to ultraviolet radiation exposure. Environmental and Molecular Mutagenesis 50:9, pages 753-759.
Crossref
Xinna Zhang, Lin Lin, Huarong Guo, Jianhua Yang, Stephen N. Jones, Aart Jochemsen & Xiongbin Lu. (2009) Phosphorylation and Degradation of MdmX Is Inhibited by Wip1 Phosphatase in the DNA Damage Response. Cancer Research 69:20, pages 7960-7968.
Crossref
David W. Meek. (2009) Tumour suppression by p53: a role for the DNA damage response?. Nature Reviews Cancer 9:10, pages 714-723.
Crossref
Chihiro Ohtsubo, Daisuke Shiokawa, Masami Kodama, Christian Gaiddon, Hitoshi Nakagama, Aart G. Jochemsen, Yoichi Taya & Koji Okamoto. (2009) Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2. Cancer Science 100:7, pages 1291-1299.
Crossref
Sarah J. Santos, Mark D. Aupperlee, Jianwei Xie, Srinivasan Durairaj, Richard Miksicek, Susan E. Conrad, Jeffrey R. Leipprandt, Ying S. Tan, Richard C. Schwartz & Sandra Z. Haslam. (2009) Progesterone receptor A-regulated gene expression in mammary organoid cultures. The Journal of Steroid Biochemistry and Molecular Biology 115:3-5, pages 161-172.
Crossref
Elizabeth A. Harker, Douglas S. Daniels, Danielle A. Guarracino & Alanna Schepartz. (2009) β-Peptides with improved affinity for hDM2 and hDMX. Bioorganic & Medicinal Chemistry 17:5, pages 2038-2046.
Crossref
Mark Wade & Geoffrey M. Wahl. (2009) Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?. Molecular Cancer Research 7:1, pages 1-11.
Crossref
Scarlett Reincke, Lina Govbakh, Bettina Wilhelm, Haiyan Jin, Natalia Bogdanova, Michael Bremer, Johann H Karstens & Thilo Dörk. (2008) Mutation analysis of the MDM4gene in German breast cancer patients. BMC Cancer 8:1.
Crossref
M Markey & S J Berberich. (2008) Full-length hdmX transcripts decrease following genotoxic stress. Oncogene 27:52, pages 6657-6666.
Crossref
Abhi Veerakumarasivam, Helen E. Scott, Suet-Feung Chin, Anne Warren, Matthew J. Wallard, Donna Grimmer, Koichi Ichimura, Carlos Caldas, V. Peter Collins, David E. Neal & John D. Kelly. (2008) High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 ( MDM4 ) as an Amplification Target Exclusive of MDM2 and TP53 . Clinical Cancer Research 14:9, pages 2527-2534.
Crossref
Vanessa Lopez-Pajares, Mihee M. Kim & Zhi-Min Yuan. (2008) Phosphorylation of MDMX Mediated by Akt Leads to Stabilization and Induces 14-3-3 Binding. Journal of Biological Chemistry 283:20, pages 13707-13713.
Crossref
K Linke, P D Mace, C A Smith, D L Vaux, J Silke & C L Day. (2008) Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death & Differentiation 15:5, pages 841-848.
Crossref
Andrea Prodosmo, Simona Giglio, Sonia Moretti, Francesca Mancini, Flavia Barbi, Nicola Avenia, Giusy Di Conza, Holger J. Schünemann, Lorenza Pistola, Vienna Ludovini, Ada Sacchi, Alfredo Pontecorvi, Efisio Puxeddu & Fabiola Moretti. (2008) Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. Journal of Molecular Medicine 86:5, pages 585-596.
Crossref
Yasmine A. Valentin-Vega, Juan A. Barboza, Gilda P. Chau, Adel K. El-Naggar & Guillermina Lozano. (2007) High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Human Pathology 38:10, pages 1553-1562.
Crossref
Baoli Hu, Daniele M. Gilkes & Jiandong Chen. (2007) Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX. Cancer Research 67:18, pages 8810-8817.
Crossref
N Gonin-Laurent, N S Hadj-Hamou, N Vogt, C Houdayer, M Gauthiers-Villars, C Dehainault, X Sastre-Garau, S Chevillard & B Malfoy. (2007) RB1 and TP53 pathways in radiation-induced sarcomas. Oncogene 26:41, pages 6106-6112.
Crossref
Yunyuan V. Wang, Mark Wade, EeTsin Wong, Yao-Cheng Li, Luo Wei Rodewald & Geoffrey M. Wahl. (2007) Quantitative analyses reveal the importance of regulated Hdmx degradation for P53 activation. Proceedings of the National Academy of Sciences 104:30, pages 12365-12370.
Crossref
Christoph R. Müller, Erik B. Paulsen, Paul Noordhuis, Florence Pedeutour, Gunnar Saeter & Ola Myklebost. (2007) Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. International Journal of Cancer 121:1, pages 199-205.
Crossref
Jean-Christophe W. Marine, Michael A. Dyer & Aart G. Jochemsen. (2007) MDMX: from bench to bedside. Journal of Cell Science 120:3, pages 371-378.
Crossref
Samuel Myllykangas, Tom Böhling & Sakari Knuutila. (2007) Specificity, selection and significance of gene amplifications in cancer. Seminars in Cancer Biology 17:1, pages 42-55.
Crossref
Xin Han, Guillermo Garcia-Manero, Timothy J McDonnell, Guillermina Lozano, L Jeffrey Medeiros, Lianchun Xiao, Gary Rosner, Martin Nguyen, Michael Fernandez, Yasmine A Valentin-Vega, Juan Barboza, Daniel M Jones, Georgios Z Rassidakis, Hagop M Kantarjian & Carlos E Bueso-Ramos. (2007) HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Modern Pathology 20:1, pages 54-62.
Crossref
Lyubomir T. Vassilev. (2007) MDM2 inhibitors for cancer therapy. Trends in Molecular Medicine 13:1, pages 23-31.
Crossref
L S M Boesten, S M Zadelaar, S De Clercq, S Francoz, A van Nieuwkoop, E A L Biessen, F Hofmann, S Feil, R Feil, A G Jochemsen, C Zurcher, L M Havekes, B J M van Vlijmen & J-C Marine. (2006) Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death & Differentiation 13:12, pages 2089-2098.
Crossref
Franck Toledo & Geoffrey M. Wahl. (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Reviews Cancer 6:12, pages 909-923.
Crossref

Displaying 200 of 225 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.